Thomas Chase

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.8 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Vanover Kimberly E; Betz Adrienne J; Weber Suzanne M; Bibbiani Francesco; Kielaite Aiste; Weiner David M; Davis Robert E; Chase Thomas N; Salamone John D
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Liang Zhong-Qin; Wang Xiaoxia; Li Ling-Yun; Wang Yumei; Chen Ren-Wu; Chuang De-Maw; Chase Thomas N; Qin Zheng-Hong
Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum.
Liang Zhong-Qin; Li Yun-Lin; Zhao Xi-Lin; Han Rong; Wang Xiao-Xia; Wang Yumei; Chase Thomas N; Bennett M Catherine; Qin Zheng-Hong
NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Thomas Chase (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Vanover Kimberly E; Betz Adrienne J; Weber Suzanne M; Bibbiani Francesco; Kielaite Aiste; Weiner David M; Davis Robert E; Chase Thomas N; Salamone John D
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Pharmacology, biochemistry, and behavior 2008;90(4):540-4.
2007: Liang Zhong-Qin; Wang Xiaoxia; Li Ling-Yun; Wang Yumei; Chen Ren-Wu; Chuang De-Maw; Chase Thomas N; Qin Zheng-Hong
Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum.
Journal of neuroscience research 2007;85(6):1295-309.
2007: Liang Zhong-Qin; Li Yun-Lin; Zhao Xi-Lin; Han Rong; Wang Xiao-Xia; Wang Yumei; Chase Thomas N; Bennett M Catherine; Qin Zheng-Hong
NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.
Brain research 2007;1145():190-203.
2007: Smith C P S; Oh J D; Bibbiani F; Collins M A; Avila I; Chase T N
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Neuropharmacology 2007;52(2):515-26.
2006: Bara-Jimenez William; Dimitrova Tzvetelina D; Sherzai Abdullah; Aksu Murat; Chase Thomas N
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Movement disorders : official journal of the Movement Disorder Society 2006;21(9):1380-3.
2006: Andringa G; Bol J G J M; Wang X; Boekel A; Bennett M C; Chase T N; Drukarch B
Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.
Neuropathology and applied neurobiology 2006;32(2):157-69.
2005: Bibbiani F; Oh J D; Kielaite A; Collins M A; Smith C; Chase T N
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Experimental neurology 2005;196(2):422-9.
2005: Liang Zhong-Qin; Wang Xiao-Xia; Wang Yumei; Chuang De-Maw; DiFiglia Marian; Chase Thomas N; Qin Zheng-Hong
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
Neurobiology of disease 2005;20(2):562-73.
2005: Bara-Jimenez William; Bibbiani Francesco; Morris Michael J; Dimitrova Tzvetelina; Sherzai Abdullah; Mouradian Maral M; Chase Thomas N
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2005;20(8):932-6.
2005: Zhang Hui-Ling; Huang Zhi Hong; Zhu Yi; Liang Zhong-Qing; Han Rong; Wang Xiao-Xia; Chase Thomas N; Qin Zheng-Hong
Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia.
Brain research 2005;1039(1-2):203-6.
2005: Bibbiani Francesco; Costantini Lauren C; Patel Raj; Chase Thomas N
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Experimental neurology 2005;192(1):73-8.
2004: Bara-Jimenez William; Dimitrova Tzvetelina; Sherzai Abdulah; Favit Antonella; Mouradian M M; Chase Thomas N
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(10):1183-6.
2004: Wessell R H; Ahmed S M; Menniti F S; Dunbar G L; Chase T N; Oh J D
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Neuropharmacology 2004;47(2):184-94.
2004: Chase Thomas N
Striatal plasticity and extrapyramidal motor dysfunction.
Parkinsonism & related disorders 2004;10(5):305-13.
2004: Andringa G; Lam K Y; Chegary M; Wang X; Chase T N; Bennett M C
Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(7):932-4.
2003: Chase T N; Bibbiani F; Bara-Jimenez W; Dimitrova T; Oh-Lee J D
Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
Neurology 2003;61(11 Suppl 6):S107-11.
2003: Kase Hiroshi; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson P J; Jenner P; Bedard P; Borrelli E; Hauser R A; Chase T N;
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Neurology 2003;61(11 Suppl 6):S97-100.
2003: Bibbiani F; Oh J D; Petzer J P; Castagnoli N; Chen J-F; Schwarzschild M A; Chase T N
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Experimental neurology 2003;184(1):285-94.
2003: Andringa Gerda; Du Fu; Chase Thomas N; Bennett M Catherine
Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies.
Journal of neuropathology and experimental neurology 2003;62(10):1060-75.
2003: Bara-Jimenez W; Sherzai A; Dimitrova T; Favit A; Bibbiani F; Gillespie M; Morris M J; Mouradian M M; Chase T N
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Neurology 2003;61(3):293-6.
2003: Blanchet Pierre J; Konitsiotis Spiros; Mochizuki Hideki; Pluta Ryszard; Emerich Dwaine F; Chase Thomas N; Mouradian M Maral
Complications of a trophic xenotransplant approach in parkinsonian monkeys.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(4):607-12.
2003: Oh Justin D; Chartisathian Karnon; Ahmed Syed M; Chase Thomas N
Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.
Journal of neuroscience research 2003;72(6):768-80.
2003: Oh Justin D; Geller Alfred I; Zhang Guo rong; Chase Thomas N
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
Brain research 2003;971(1):18-30.
2003: Chase Thomas N; Bibbiani Francesco; Oh Justin D
Striatal glutamatergic mechanisms and extrapyramidal movement disorders.
Neurotoxicity research 2003;5(1-2):139-46.
2003: Blanchet Pierre J; Metman Leo Verhagen; Chase Thomas N
Renaissance of amantadine in the treatment of Parkinson's disease.
Advances in neurology 2003;91():251-7.
2002: Wang Xiaoxia; Qin Zheng-Hong; Leng Yan; Wang Yumei; Jin Xiannu; Chase Thomas N; Bennett M Catherine
Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells.
Journal of neurochemistry 2002;83(5):1094-102.
2002: Oh Justin D; Bibbiani Francesco; Chase Thomas N
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Experimental neurology 2002;177(2):557-64.
2002: Tessitore Alessandro; Hariri Ahmad R; Fera Francesco; Smith William G; Chase Thomas N; Hyde Thomas M; Weinberger Daniel R; Mattay Venkata S
Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(20):9099-103.
2002: Verhagen Metman L; Morris M J; Farmer C; Gillespie M; Mosby K; Wuu J; Chase T N
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Neurology 2002;59(5):694-9.
2002: Jeffries K J; Schooler C; Schoenbach C; Herscovitch P; Chase T N; Braun A R
The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;27(1):92-104.
2002: Mattay Venkata S; Tessitore Alessandro; Callicott Joseph H; Bertolino Alessandro; Goldberg Terry E; Chase Thomas N; Hyde Thomas M; Weinberger Daniel R
Dopaminergic modulation of cortical function in patients with Parkinson's disease.
Annals of neurology 2002;51(2):156-64.
2002: Oh J D; Chase T N
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Amino acids 2002;23(1-3):133-9.
2001: Bibbiani F; Oh J D; Chase T N
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
Neurology 2001;57(10):1829-34.
2001: Leng Y; Chase T N; Bennett M C
Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm.
The Journal of biological chemistry 2001;276(30):28212-8.
2001: Del Dotto P; Pavese N; Gambaccini G; Bernardini S; Metman L V; Chase T N; Bonuccelli U
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Movement disorders : official journal of the Movement Disorder Society 2001;16(3):515-20.
2001: Hutton J T; Metman L V; Chase T N; Juncos J L; Koller W C; Pahwa R; LeWitt P A; Samii A; Tsui J K; Calne D B; Waters C H; Calabrese V P; Bennett J P; Barrett R; Morris J L
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
Movement disorders : official journal of the Movement Disorder Society 2001;16(3):459-63.
2001: Metman L V; Gillespie M; Farmer C; Bibbiani F; Konitsiotis S; Morris M; Shill H; Bara-Jimenez W; Mouradian M M; Chase T N
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Clinical neuropharmacology 2001;24(3):163-9.
2001: Qin Z H; Wang Y; Chen R W; Wang X; Ren M; Chuang D M; Chase T N
Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum.
The Journal of pharmacology and experimental therapeutics 2001;297(1):78-87.
2001: Shoulson I; Penney J; McDermott M; Schwid S; Kayson E; Chase T; Fahn S; Greenamyre J T; Lang A; Siderowf A; Pearson N; Harrison M; Rost E; Colcher A; Lloyd M; Matthews M; Pahwa R; McGuire D; Lew M F; Schuman S; Marek K; Broshjeit S; Factor S; Brown D; Feigin A; Mazurkiewicz J; Ford B; Jennings D; Dilllon S; Comella C; Blasucci L; Janko K; Shulman L; Wiener W; Bateman-Rodriguez D; Carrion A; Suchowersky O; Lafontaine A L; Pantella C; Siemers E; Belden J; Davies R; Lannon M; Grimes D; Gray P; Martin W; Kennedy L; Adler C; Newman S; Hammerstad J; Stone C; Lewitt P; Bardram K; Mistura K; Miyasaki J; Johnston L; Cha J H; Tennis M; Panniset M; Hall J; Tetrud J; Friedlander J; Hauser R; Gauger L; Rodnitzky R; Deleo A; Dobson J; Seeberger L; Dingmann C; Tarsy D; Ryan P; Elmer L; Ruzicka D; Stacy M; Brewer M; Locke B; Baker D; Casaceli C; Day D; Florack M; Hodgeman K; Laroia N; Nobel R; Orme C; Rexo L; Rothenburgh K; Sulimowicz K; Watts A; Wratni E; Tariot P; Cox C; Leventhal C; Alderfer V; Craun A M; Frey J; McCree L; McDermott J; Cooper J; Holdich T; Read B;
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.
Neurology 2001;56(4):455-62.
2001: Chase T N; Konitsiotis S; Oh J D
Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
Advances in neurology 2001;86():355-60.
2000: Chase T N; Oh J D
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
Trends in neurosciences 2000;23(10 Suppl):S86-91.
2000: Marin C; Jimenez A; Bonastre M; Chase T N; Tolosa E
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Synapse (New York, N.Y.) 2000;36(4):267-74.
2000: Chase T N; Oh J D; Konitsiotis S
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
Journal of neurology 2000;247 Suppl 2():II36-42.
2000: Konitsiotis S; Blanchet P J; Verhagen L; Lamers E; Chase T N
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Neurology 2000;54(8):1589-95.
2000: Chase T N; Oh J D
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Annals of neurology 2000;47(4 Suppl 1):S122-9; discussion S129-30.
2000: Nakai M; Qin Z; Wang Y; Chase T N
NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117.
Brain research 2000;859(2):207-16.
2000: Nakai M; Qin Z H; Chen J F; Wang Y; Chase T N
Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation.
Journal of neurochemistry 2000;74(2):647-58.
2000: Oh J D; Chartisathian K; Chase T N; Butcher L L
Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain.
Brain research 2000;853(2):174-85.
2000: Metman L V; Konitsiotis S; Chase T N
Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Movement disorders : official journal of the Movement Disorder Society 2000;15(1):3-8.
1999: Agid Y; Ahlskog E; Albanese A; Calne D; Chase T; De Yebenes J; Factor S; Fahn S; Gershanik O; Goetz C; Koller W; Kurth M; Lang A; Lees A; Lewitt P; Marsden D; Melamed E; Michel P P; Mizuno Y; Obeso J; Oertel W; Olanow W; Poewe W; Pollak P; Tolosa E
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Movement disorders : official journal of the Movement Disorder Society 1999;14(6):911-3.
1999: Bennett M C; Bishop J F; Leng Y; Chock P B; Chase T N; Mouradian M M
Degradation of alpha-synuclein by proteasome.
The Journal of biological chemistry 1999;274(48):33855-8.
1999: Metman L V; Del Dotto P; LePoole K; Konitsiotis S; Fang J; Chase T N
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Archives of neurology 1999;56(11):1383-6.
1999: Blanchet P J; Konitsiotis S; Whittemore E R; Zhou Z L; Woodward R M; Chase T N
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
The Journal of pharmacology and experimental therapeutics 1999;290(3):1034-40.
1999: Blanchet P J; Fang J; Hyland K; Arnold L A; Mouradian M M; Chase T N
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.
Neurology 1999;53(1):91-5.
1999: Qin Z H; Chen R W; Wang Y; Nakai M; Chuang D M; Chase T N
Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1999;19(10):4023-33.
1999: Oh J D; Vaughan C L; Chase T N
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Brain research 1999;821(2):433-42.
1999: Nakai M; Qin Z H; Wang Y; Chase T N
Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum.
Brain research. Molecular brain research 1999;64(1):59-68.
1999: Wang Y; Qin Z H; Nakai M; Chen R W; Chuang D M; Chase T N
Co-stimulation of cyclic-AMP-linked metabotropic glutamate receptors in rat striatum attenuates excitotoxin-induced nuclear factor-kappaB activation and apoptosis.
Neuroscience 1999;94(4):1153-62.
1998: Blanchet P J; Fang J; Gillespie M; Sabounjian L; Locke K W; Gammans R; Mouradian M M; Chase T N
Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
Clinical neuropharmacology 1998;21(6):339-43.
1998: Oh J D; Russell D S; Vaughan C L; Chase T N;
Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.
Brain research 1998;813(1):150-9.
1998: Blanchet P J; Konitsiotis S; Hyland K; Arnold L A; Pettigrew K D; Chase T N
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Experimental neurology 1998;153(2):214-22.
1998: Blanchet P J; Konitsiotis S; Chase T N
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Movement disorders : official journal of the Movement Disorder Society 1998;13(5):798-802.
1998: Fahn S; Clarence-Smith K E; Chase T N
Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop.
Movement disorders : official journal of the Movement Disorder Society 1998;13(5):759-67.
1998: Chase T N; Oh J D; Blanchet P J
Neostriatal mechanisms in Parkinson's disease.
Neurology 1998;51(2 Suppl 2):S30-5.
1998: Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase T N
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Neurology 1998;51(1):203-6.
1998: Randolph C; Tierney M C; Mohr E; Chase T N
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.
Journal of clinical and experimental neuropsychology 1998;20(3):310-9.
1998: Verhagen Metman L; Blanchet P J; van den Munckhof P; Del Dotto P; Natté R; Chase T N
A trial of dextromethorphan in parkinsonian patients with motor response complications.
Movement disorders : official journal of the Movement Disorder Society 1998;13(3):414-7.
1998: Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian M M; Chase T N
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Neurology 1998;50(5):1323-6.
1998: Chase T N
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
Neurology 1998;50(5 Suppl 5):S17-25.
1998: van den Munckhof P; Lenz F A; Chase T N
Square-wave action dystonia in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):354-6.
1998: Agid Y; Chase T; Marsden D
Adverse reactions to levodopa: drug toxicity or progression of disease?
Lancet 1998;351(9106):851-2.
1998: Qin Z H; Wang Y; Nakai M; Chase T N
Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum.
Molecular pharmacology 1998;53(1):33-42.
1998: Verhagen Metman L; Del Dotto P; Blanchet P J; van den Munckhof P; Chase T N
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Amino acids 1998;14(1-3):75-82.
1998: Chase T N
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Drugs 1998;55 Suppl 1():1-9.
1997: Blanchet P J; Konitsiotis S; Chase T N
Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
The Journal of pharmacology and experimental therapeutics 1997;283(2):794-9.
1997: Wang Y; Qin Z H; Nakai M; Chase T N
Glutamate metabotropic receptor agonist 1S,3R-ACPD induces internucleosomal DNA fragmentation and cell death in rat striatum.
Brain research 1997;772(1-2):45-56.
1997: Chase T N
A gene for Parkinson disease.
Archives of neurology 1997;54(9):1156-7.
1997: Metman L V; van den Munckhof P; Klaassen A A; Blanchet P; Mouradian M M; Chase T N
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
Neurology 1997;49(3):711-3.
1997: Blanchet P J; Papa S M; Metman L V; Mouradian M M; Chase T N
Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
Neuroscience and biobehavioral reviews 1997;21(4):447-53.
1997: Mouradian M M; Chase T N
Gene therapy for Parkinson's disease: current knowledge and future perspective.
Gene therapy 1997;4(6):504-6.
1997: Oh J D; Del Dotto P; Chase T N
Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat.
Neuroscience letters 1997;228(1):5-8.
1997: Mouradian M M; Chase T N
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Experimental neurology 1997;144(1):51-7.
1997: Oyanagi K; Makifuchi T; Ohtoh T; Chen K M; Gajdusek D C; Chase T N
Distinct pathological features of the gallyas- and tau-positive glia in the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
Journal of neuropathology and experimental neurology 1997;56(3):308-16.
1997: Verhagen Metman L; Locatelli E R; Bravi D; Mouradian M M; Chase T N
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Neurology 1997;48(2):369-72.
1996: Marin C; Papa S; Engber T M; Bonastre M; Tolosa E; Chase T N
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Brain research 1996;736(1-2):202-5.
1996: Blesa R; Mohr E; Miletich R S; Hildebrand K; Sampson M; Chase T N
Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns.
Dementia (Basel, Switzerland) 1996;7(5):239-45.
1996: Blanchet P J; Metman L V; Mouradian M M; Chase T N
Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(5):580-1.
1996: Tedeschi G; Bertolino A; Lundbom N; Bonavita S; Patronas N J; Duyn J H; Metman L V; Chase T N; Di Chiro G
Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging.
Neurology 1996;47(3):696-704.
1996: Marin C; Engber T M; Bonastre M; Chase T N; Tolosa E
Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior.
Brain research 1996;731(1-2):57-62.
1996: Qin Z H; Wang Y; Chase T N
Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain.
Brain research 1996;725(2):166-76.
1996: Metman L V; Blanchet P J; de Jong D; Mouradian M M; Chase T N
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(3):257-60.
1996: Papa S M; Chase T N
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Annals of neurology 1996;39(5):574-8.
1996: Marin C; Engber T M; Chaudhuri P; Peppe A; Chase T N
Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors.
Psychopharmacology 1996;123(2):215-21.
1996: Anderson J J; Kask A M; Chase T N
Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists.
European journal of pharmacology 1996;295(2-3):163-8.
1996: Chase T N; Engber T M; Mouradian M M
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
Advances in neurology 1996;69():497-501.
1995: Papa S M; Boldry R C; Engber T M; Kask A M; Chase T N
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Brain research 1995;701(1-2):13-8.
1995: Braun A R; Randolph C; Stoetter B; Mohr E; Cox C; Vladar K; Sexton R; Carson R E; Herscovitch P; Chase T N
The functional neuroanatomy of Tourette's syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1995;13(2):151-68.
1995: Blesa R; Mohr E; Miletich R S; Chase T N
Limbic system dysfunction in Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry 1995;59(4):450-1.
1995: Anderson L A; Anderson J J; Chase T N; Walters J R
The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.
Brain research 1995;691(1-2):106-14.
1995: Boldry R C; Papa S M; Kask A M; Chase T N
MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
Brain research 1995;692(1-2):259-64.
1995: Anderson J J; Randall S; Chase T N
The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
The Journal of pharmacology and experimental therapeutics 1995;274(2):928-36.
1995: Chase T N; Tamminga C A
Alzheimer's dementia.
The American journal of psychiatry 1995;152(8):1110.
1995: Marin C; Chase T N
Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors.
Neuropharmacology 1995;34(6):677-82.
1995: Randolph C; Tierney M C; Chase T N
Implicit memory in Alzheimer's disease.
Journal of clinical and experimental neuropsychology 1995;17(3):343-51.
1994: Oyanagi K; Makifuchi T; Ohtoh T; Ikuta F; Chen K M; Chase T N; Gajdusek D C
Topographic investigation of brain atrophy in parkinsonism-dementia complex of Guam: a comparison with Alzheimer's disease and progressive supranuclear palsy.
Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration 1994;3(4):301-4.
1994: Engber T M; Papa S M; Boldry R C; Chase T N
NMDA receptor blockade reverses motor response alterations induced by levodopa.
Neuroreport 1994;5(18):2586-8.
1994: Papa S M; Engber T M; Kask A M; Chase T N
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Brain research 1994;662(1-2):69-74.
1994: Metman L V; Sethy V H; Roberts J R; Bravi D; Hoff J I; Mouradian M M; Chase T N
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):577-81.
1994: Anderson J J; Kuo S; Chase T N
Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors.
Neuroscience letters 1994;176(2):264-8.
1994: Litvan I; Blesa R; Clark K; Nichelli P; Atack J R; Mouradian M M; Grafman J; Chase T N
Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
Annals of neurology 1994;36(1):55-61.
1994: Bravi D; Mouradian M M; Roberts J W; Davis T L; Sohn Y H; Chase T N
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Annals of neurology 1994;36(1):27-31.
1994: Metman L V; Hoff J; Mouradian M M; Chase T N
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Movement disorders : official journal of the Movement Disorder Society 1994;9(4):463-5.
1994: Chase T N; Engber T M; Mouradian M M
Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
Neurology 1994;44(7 Suppl 6):S15-8.
1994: Anderson J J; Kuo S; Chase T N; Engber T M
Dopamine D1 receptor-stimulated release of acetylcholine in rat striatum is mediated indirectly by activation of striatal neurokinin1 receptors.
The Journal of pharmacology and experimental therapeutics 1994;269(3):1144-51.
1994: Blin J; Piercey M F; Giuffra M E; Mouradian M M; Chase T N
Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.
Journal of the neurological sciences 1994;123(1-2):44-51.
1994: Sohn Y H; Metman L V; Bravi D; Linfante I; Aotsuka A; Mouradian M M; Chase T N
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Neurology 1994;44(4):755-7.
1994: Engber T M; Anderson J J; Boldry R C; Papa S M; Kuo S; Chase T N
Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.
Neuroscience 1994;59(2):389-99.
1994: Blin J; Ray C A; Piercey M F; Bartko J J; Mouradian M M; Chase T N
Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.
Brain research 1994;635(1-2):196-202.
1994: Randolph C; Roberts J W; Tierney M C; Bravi D; Mouradian M M; Chase T N
D-cycloserine treatment of Alzheimer disease.
Alzheimer disease and associated disorders 1994;8(3):198-205.
1994: Oyanagi K; Makifuchi T; Ohtoh T; Chen K M; Gajdusek D C; Chase T N; Ikuta F
The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy.
Acta neuropathologica 1994;88(2):122-8.
1994: Oyanagi K; Makifuchi T; Ohtoh T; Chen K M; van der Schaaf T; Gajdusek D C; Chase T N; Ikuta F
Amyotrophic lateral sclerosis of Guam: the nature of the neuropathological findings.
Acta neuropathologica 1994;88(5):405-12.
1993: Braun A R; Stoetter B; Randolph C; Hsiao J K; Vladar K; Gernert J; Carson R E; Herscovitch P; Chase T N
The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1993;9(4):277-91.
1993: Chase T N; Mouradian M M; Engber T M
Motor response complications and the function of striatal efferent systems.
Neurology 1993;43(12 Suppl 6):S23-7.
1993: Roberts J W; Cora-Locatelli G; Bravi D; Amantea M A; Mouradian M M; Chase T N
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Neurology 1993;43(12):2685-8.
1993: Boldry R C; Chase T N; Engber T M
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
The Journal of pharmacology and experimental therapeutics 1993;267(3):1454-9.
1993: Bravi D; Mouradian M M; Roberts J W; Davis T L; Chase T N
End-of-dose dystonia in Parkinson's disease.
Neurology 1993;43(10):2130-1.
1993: Anderson J J; Kuo S; Chase T N; Engber T M
GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo.
Neuroscience letters 1993;160(2):126-30.
1993: Giuffra M; Mouradian M M; Davis T L; Ownby J; Chase T N
Dynorphin agonist therapy of Parkinson's disease.
Clinical neuropharmacology 1993;16(5):444-7.
1993: Anderson J J; Chase T N; Engber T M
Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats.
Brain research 1993;623(2):189-94.
1993: Randolph C; Mohr E; Chase T N
Assessment of intellectual function in dementing disorders: validity of WAIS-R short forms for patients with Alzheimer's, Huntington's, and Parkinson's disease.
Journal of clinical and experimental neuropsychology 1993;15(5):743-53.
1993: Roberts J W; Hoeg J M; Mouradian M M; Linfante I; Chase T N
Iatrogenic hyperlipidaemia with GM1 ganglioside.
Lancet 1993;342(8863):115.
1993: Engber T M; Marin C; Susel Z; Chase T N
Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
European journal of pharmacology 1993;236(3):385-93.
1993: Engber T M; Anderson J J; Boldry R C; Kuo S; Chase T N
N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Neuroscience 1993;54(4):1051-61.
1993: Marin C; Parashos S A; Kapitzoglou-Logothetis V; Peppe A; Chase T N
D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Pharmacology, biochemistry, and behavior 1993;45(1):195-200.
1993: Anderson J J; Bravi D; Ferrari R; Davis T L; Baronti F; Chase T N; Dagani F
No evidence for altered muscle mitochondrial function in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1993;56(5):477-80.
1993: Jauch D A; Sethy V H; Weick B G; Chase T N; Schwarcz R
Intravenous administration of L-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid.
Neuropharmacology 1993;32(5):467-72.
1993: Bravi D; Davis T L; Mouradian M M; Chase T N
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Movement disorders : official journal of the Movement Disorder Society 1993;8(2):195-7.
1993: Papa S M; Engber T M; Boldry R C; Chase T N
Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
European journal of pharmacology 1993;232(2-3):247-53.
1993: Marin C; Chase T N
Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
European journal of pharmacology 1993;231(2):191-6.
1993: Boldry R C; Kelland M D; Engber T M; Chase T N
NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens.
Brain research 1993;600(2):331-4.
1993: Peppe A; Dambrosia J M; Chase T N
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Advances in neurology 1993;60():698-702.
1993: Chase T N; Engber T M; Mouradian M M
Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Advances in neurology 1993;60():181-5.
1993: Giuffra M E; Sethy V H; Davis T L; Mouradian M M; Chase T N
Milacemide therapy for Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8(1):47-50.
1992: Baronti F; Mouradian M M; Davis T L; Giuffra M; Brughitta G; Conant K E; Chase T N
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Annals of neurology 1992;32(6):776-81.
1992: Ray C A; Blin J; Chase T N; Piercey M F
Effects of cholinergic agonists on regional brain energy metabolism in the scopolamine-treated rat.
Neuropharmacology 1992;31(11):1193-9.
1992: Mann U M; Mohr E; Gearing M; Chase T N
Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles.
Journal of neurology, neurosurgery, and psychiatry 1992;55(10):956-9.
1992: Dagani F; Anderson J J; Chase T N
Mitochondrial function in Parkinson's disease.
Annals of neurology 1992;32(2):226-7.
1992: Litvan I; Berrettini W H; Atack J R; Chase T N
CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy.
Acta neurologica Scandinavica 1992;86(2):204-6.
1992: Anderson J J; Chase T N; Engber T M
Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats.
Brain research 1992;588(2):307-10.
1992: Tamminga C A; Thaker G K; Buchanan R; Kirkpatrick B; Alphs L D; Chase T N; Carpenter W T
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.
Archives of general psychiatry 1992;49(7):522-30.
1992: Baronti F; Mouradian M M; Conant K E; Giuffra M; Brughitta G; Chase T N
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
Neurology 1992;42(6):1241-3.
1992: Mohr E; Mann U M; Miletich R S; Sampson M; Goldberg T E; Grimes J D; Chase T N
Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1992;19(2):163-9.
1992: Engber T M; Boldry R C; Kuo S; Chase T N
Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
Brain research 1992;581(2):261-8.
1992: Giuffra M E; Mouradian M M; Chase T N
Glutamatergic therapy of Huntington's chorea.
Clinical neuropharmacology 1992;15(2):148-51.
1992: Baronti F; Davis T L; Boldry R C; Mouradian M M; Chase T N
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Neurology 1992;42(3 Pt 1):541-4.
1992: Heuser I J; Baronti F; Marin C A; Ma N; Merriam G R; Chase T N; Mouradian M M
Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies.
Neurobiology of aging 1992;13(2):255-60.
1992: Engber T M; Susel Z; Weick B G; Walters J R; Chase T N
Effects of chronic levodopa on D1 and D2 receptor-mediated striatal output.
Neurochemistry international 1992;20 Suppl():255S-260S.
1992: Naber D; Weinberger D R; Gillespie M; Chase T N
Failure of buspirone and verapamil to improve spasmodic torticollis.
The Journal of neuropsychiatry and clinical neurosciences 1992;4(1):82-4.
1992: Bravi D; Anderson J J; Dagani F; Davis T L; Ferrari R; Gillespie M; Chase T N
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1992;7(3):228-31.
1992: Weinberger D R; Jones D; Reba R C; Mann U; Coppola R; Gibson R; Gorey J; Braun A; Chase T N
A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
The Journal of neuropsychiatry and clinical neurosciences 1992;4(3):239-48.
1992: Cohen D J; Friedhoff A J; Leckman J F; Chase T N
Tourette syndrome. Extending basic research to clinical care.
Advances in neurology 1992;58():341-62.
1992: Stoetter B; Braun A R; Randolph C; Gernert J; Carson R E; Herscovitch P; Chase T N
Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studied with FDG PET.
Advances in neurology 1992;58():213-26.
1991: Blin J; Ray C A; Chase T N; Piercey M F
Regional cerebral glucose metabolism compared in rodents and humans.
Brain research 1991;568(1-2):215-22.
1991: Baronti F; Ruggieri S; Mouradian M M; Bonamartini A; Bocciarelli P; De Pandis M F; Chase T N; Agnoli A
[Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease]
Rivista di neurologia 1991;61(6):210-4.
1991: Heuser I J; Chase T N; Mouradian M M
The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease.
Biological psychiatry 1991;30(9):943-52.
1991: Mouradian M M; Blin J; Giuffra M; Heuser I J; Baronti F; Ownby J; Chase T N
Somatostatin replacement therapy for Alzheimer dementia.
Annals of neurology 1991;30(4):610-3.
1991: Atack J R; Litvan I; Thal L J; May C; Rapoport S I; Chase T N
Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
Journal of neurology, neurosurgery, and psychiatry 1991;54(9):832-5.
1991: Baronti F; Conant K E; Giuffra M; Davis T L; Brughitta G; Iadarola M J; Berrettini W H; Chase T N; Mouradian M M
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Brain research 1991;560(1-2):92-6.
1991: Engber T M; Boldry R C; Chase T N
The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists.
European journal of pharmacology 1991;200(1):171-3.
1991: Engber T M; Susel Z; Kuo S; Gerfen C R; Chase T N
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Brain research 1991;552(1):113-8.
1991: Mouradian M M; Heuser I J; Baronti F; Giuffra M; Conant K; Davis T L; Chase T N
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(5):401-5.
1991: Claus J J; Ludwig C; Mohr E; Giuffra M; Blin J; Chase T N
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.
Neurology 1991;41(4):570-4.
1991: Ariano M A; Engber T M; Susel Z; Chase T N
Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.
Experimental neurology 1991;112(1):112-8.
1991: Claus J J; Mohr E; Chase T N
Clinical trials in dementia: learning effects with repeated testing.
Journal of psychiatry & neuroscience : JPN 1991;16(1):1-4.
1991: Marin C; Parashos S A; Chase T N
Effect of Gi protein ADP-ribosylation induced by pertussis toxin on dopamine-mediated behaviors.
European journal of pharmacology 1991;195(1):19-25.
1991: Litvan I; Mohr E; Williams J; Gomez C; Chase T N
Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(1):25-9.
1991: Susel Z; Engber T M; Kuo S; Chase T N
Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease.
Neuroscience letters 1991;121(1-2):234-8.
1991: Mohr E; Brouwers P; Claus J J; Mann U M; Fedio P; Chase T N
Visuospatial cognition in Huntington's disease.
Movement disorders : official journal of the Movement Disorder Society 1991;6(2):127-32.
1991: Dagani F; Ferrari R; Anderson J J; Chase T N
L-dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria.
Movement disorders : official journal of the Movement Disorder Society 1991;6(4):315-9.
1990: Gerfen C R; Engber T M; Mahan L C; Susel Z; Chase T N; Monsma F J; Sibley D R
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
Science (New York, N.Y.) 1990;250(4986):1429-32.
1990: Engber T M; Susel Z; Kuo S; Chase T N
Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1990;10(12):3889-95.
1990: Mohr E; Mann U M; Chase T N
Subgroups in Alzheimer's disease: fact or fiction?
Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Université d'Ottawa 1990;15(4):203-6.
1990: Mohr E; Litvan I; Williams J; Fedio P; Chase T N
Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1990;17(3):292-7.
1990: Mohr E; Juncos J; Cox C; Litvan I; Fedio P; Chase T N
Selective deficits in cognition and memory in high-functioning parkinsonian patients.
Journal of neurology, neurosurgery, and psychiatry 1990;53(7):603-6.
1990: Weick B G; Engber T M; Susel Z; Chase T N; Walters J R
Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration.
Brain research 1990;523(1):16-22.
1990: Grafman J; Litvan I; Gomez C; Chase T N
Frontal lobe function in progressive supranuclear palsy.
Archives of neurology 1990;47(5):553-8.
1990: Mohr E; Cox C; Williams J; Chase T N; Fedio P
Impairment of central auditory function in Alzheimer's disease.
Journal of clinical and experimental neuropsychology 1990;12(2):235-46.
1990: Mouradian M M; Heuser I J; Baronti F; Chase T N
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Annals of neurology 1990;27(1):18-23.
1990: Pan H S; Engber T M; Chase T N; Walters J R
The effects of striatal lesion on turning behavior and globus pallidus single unit response to dopamine agonist administration.
Life sciences 1990;46(1):73-80.
1990: Weinberger D R; Mann U; Gibson R E; Coppola R; Jones D W; Braun A R; Berman K F; Sunderland T; Reba R C; Chase T N
Cerebral muscarinic receptors in primary degenerative dementia as evaluated by SPECT with iodine-123-labeled QNB.
Advances in neurology 1990;51():147-50.
1990: Parashos S A; Marin C; Barone P; Kapitzoglou-Logothetis V; Chase T N
Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.
Psychopharmacology 1990;102(3):411-3.
1990: Chase T N; Fabbrini G; Juncos J L; Mouradian M M
Motor response complications with chronic levodopa therapy.
Advances in neurology 1990;53():377-81.
1990: Barone P; Parashos S A; Palma V; Marin C; Campanella G; Chase T N
Dopamine D1 receptor modulation of pilocarpine-induced convulsions.
Neuroscience 1990;34(1):209-17.
1989: Chase T N; Baronti F; Fabbrini G; Heuser I J; Juncos J L; Mouradian M M
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Neurology 1989;39(11 Suppl 2):7-10; discussion 19.
1989: Mourdian M M; Heyes M P; Pan J B; Heuser I J; Markey S P; Chase T N; Mouradian M M
No changes in central quinolinic acid levels in Alzheimer's disease.
Neuroscience letters 1989;105(1-2):233-8.
1989: Parashos S A; Marin C; Chase T N
Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.
Neuroscience letters 1989;105(1-2):169-73.
1989: Litvan I; Gomez C; Atack J R; Gillespie M; Kask A M; Mouradian M M; Chase T N
Physostigmine treatment of progressive supranuclear palsy.
Annals of neurology 1989;26(3):404-7.
1989: Engber T M; Susel Z; Juncos J L; Chase T N
Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.
European journal of pharmacology 1989;168(3):291-8.
1989: Mann U M; Mohr E; Chase T N
Rapidly progressive Alzheimer's disease.
Lancet 1989;2(8666):799.
1989: Susel Z; Engber T M; Chase T N
Behavioral evaluation of the anti-excitotoxic properties of MK-801: comparison with neurochemical measurements.
Neuroscience letters 1989;104(1-2):125-9.
1989: Litvan I; Grafman J; Gomez C; Chase T N
Memory impairment in patients with progressive supranuclear palsy.
Archives of neurology 1989;46(7):765-7.
1989: Mouradian M M; Heuser I J; Baronti F; Fabbrini G; Juncos J L; Chase T N
Pathogenesis of dyskinesias in Parkinson's disease.
Annals of neurology 1989;25(5):523-6.
1989: Juncos J L; Engber T M; Raisman R; Susel Z; Thibaut F; Ploska A; Agid Y; Chase T N
Continuous and intermittent levodopa differentially affect basal ganglia function.
Annals of neurology 1989;25(5):473-8.
1989: Braun A; Mouradian M M; Mohr E; Fabbrini G; Chase T N
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Journal of neurology, neurosurgery, and psychiatry 1989;52(5):631-5.
1989: Mohr E; Schlegel J; Fabbrini G; Williams J; Mouradian M M; Mann U M; Claus J J; Fedio P; Chase T N
Clonidine treatment of Alzheimer's disease.
Archives of neurology 1989;46(4):376-8.
1989: Barone P; Palma V; Parashos S A; Marin C; Chase T N; Campanella G
D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine.
Bollettino della Società italiana di biologia sperimentale 1989;65(4):337-41.
1989: Schlegel J; Mohr E; Williams J; Mann U; Gearing M; Chase T N
Guanfacine treatment of Alzheimer's disease.
Clinical neuropharmacology 1989;12(2):124-8.
1989: Parashos S A; Barone P; Marin C A; Paraschos A J; Kapitzoglou-Logothetis V; Chase T N
Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat.
Psychopharmacology 1989;98(2):189-92.
1989: Mohr E; Fabbrini G; Williams J; Schlegel J; Cox C; Fedio P; Chase T N
Dopamine and memory function in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1989;4(2):113-20.
1988: Engber T M; Chase T N
Dextromethorphan does not protect against quinolinic acid neurotoxicity in rat striatum.
Neuroscience letters 1988;95(1-3):269-74.
1988: Mouradian M M; Contreras P C; Monahan J B; Chase T N
[3H]MK-801 binding in Alzheimer's disease.
Neuroscience letters 1988;93(2-3):225-30.
1988: Chase T N; Juncos J L; Fabbrini G; Mouradian M M
Motor response complications in advanced Parkinson's disease.
Functional neurology 1988;3(4):429-36.
1988: Mouradian M M; Juncos J L; Fabbrini G; Schlegel J; Bartko J J; Chase T N
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Annals of neurology 1988;24(3):372-8.
1988: Fabbrini G; Mouradian M M; Juncos J L; Schlegel J; Mohr E; Chase T N
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Annals of neurology 1988;24(3):366-71.
1988: Mouradian M M; Chase T N
Central mechanisms and levodopa response fluctuations in Parkinson's disease.
Clinical neuropharmacology 1988;11(4):378-85.
1988: Dawson T M; Barone P; Sidhu A; Wamsley J K; Chase T N
The D1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand.
Neuroscience 1988;26(1):83-100.
1988: Agui T; Chase T N; Kebabian J W
Identification of D1-dopamine receptor in chicken embryo retina with [125I]SCH 23982.
Brain research 1988;452(1-2):49-56.
1988: Barone P; Tucci I; Parashos S A; Chase T N
Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade.
European journal of pharmacology 1988;149(3):225-32.
1988: Sheridan P H; Sato S; Foster N; Bruno G; Cox C; Fedio P; Chase T N
Relation of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry.
Neurology 1988;38(5):747-50.
1988: Mouradian M M; Mohr E; Williams J A; Chase T N
No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
Neurology 1988;38(4):606-8.
1988: Naber D; Weinberger D R; Bullinger M; Polsby M; Chase T N
Personality variables, neurological and psychopathological symptoms in patients suffering from spasmodic torticollis.
Comprehensive psychiatry 1988;29(2):182-7.
1988: Braun A R; Chase T N
Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists.
European journal of pharmacology 1988;147(3):441-51.
1988: Pullman S L; Watts R L; Juncos J L; Chase T N; Sanes J N
Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease.
Neurology 1988;38(2):249-54.
1988: Chase T N; Tamminga C A; Burrows H
Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia.
Advances in neurology 1988;50():237-41.
1988: Chase T N; Mouradian M M; Fabbrini G; Juncos J L
Pathogenetic studies of motor fluctuations in Parkinson's disease.
Journal of neural transmission. Supplementum 1988;27():3-10.
1988: Weinberger D R; Berman K F; Chase T N
Mesocortical dopaminergic function and human cognition.
Annals of the New York Academy of Sciences 1988;537():330-8.
1988: Fabbrini G; Braun A; Mouradian M M; Tamminga C A; Chase T N
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Journal of neural transmission 1988;71(3):159-63.
1988: Tamminga C A; Burrows G H; Chase T N; Alphs L D; Thaker G K
Dopamine neuronal tracts in schizophrenia: their pharmacology and in vivo glucose metabolism.
Annals of the New York Academy of Sciences 1988;537():443-50.
1987: Tanimoto K; Tamminga C A; Chase T N
Elevation of plasma prolactin concentrations by intravenous SCH 23390 and SKF 38393 in conscious rats.
European journal of pharmacology 1987;144(2):147-51.
1987: Parashos S A; Barone P; Tucci I; Chase T N
Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade.
Life sciences 1987;41(20):2279-84.
1987: Juncos J L; Fabbrini G; Mouradian M M; Chase T N
Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Archives of neurology 1987;44(10):1010-2.
1987: Juncos J L; Fabbrini G; Mouradian M M; Serrati C; Chase T N
Dietary influences on the antiparkinsonian response to levodopa.
Archives of neurology 1987;44(10):1003-5.
1987: Mouradian M M; Juncos J L; Fabbrini G; Chase T N
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Annals of neurology 1987;22(4):475-9.
1987: Barone P; Bankiewicz K S; Corsini G U; Kopin I J; Chase T N
Dopaminergic mechanisms in hemiparkinsonian monkeys.
Neurology 1987;37(10):1592-5.
1987: Mohr E; Fabbrini G; Ruggieri S; Fedio P; Chase T N
Cognitive concomitants of dopamine system stimulation in parkinsonian patients.
Journal of neurology, neurosurgery, and psychiatry 1987;50(9):1192-6.
1987: Chase T N; Burrows G H; Mohr E
Cortical glucose utilization patterns in primary degenerative dementias of the anterior and posterior type.
Archives of gerontology and geriatrics 1987;6(3):289-97.
1987: Mouradian M M; Juncos J L; Serrati C; Fabbrini G; Palmeri S; Chase T N
Exercise and the antiparkinsonian response to levodopa.
Clinical neuropharmacology 1987;10(4):351-5.
1987: Tamminga C A; Tanimoto K; Kuo S; Beck M; Chase T N
Central cholecystokinin octapeptide reduces glucose utilization in subcortical but not cortical rat brain.
European journal of pharmacology 1987;139(2):237-41.
1987: Juncos J L; Mouradian M M; Fabbrini G; Serrati C; Chase T N
Levodopa methyl ester treatment of Parkinson's disease.
Neurology 1987;37(7):1242-5.
1987: Tanimoto K; Tamminga C A; Chase T N; Nilaver G
Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide.
Endocrinology 1987;121(1):127-32.
1987: Barone P; Tucci I; Parashos S A; Chase T N
D-1 dopamine receptor changes after striatal quinolinic acid lesion.
European journal of pharmacology 1987;138(1):141-5.
1987: Fabbrini G; Juncos J L; Mouradian M M; Serrati C; Chase T N
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Neurology 1987;37(5):856-9.
1987: Walters J R; Bergstrom D A; Carlson J H; Chase T N; Braun A R
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects.
Science (New York, N.Y.) 1987;236(4802):719-22.
1987: Fabbrini G; Juncos J; Mouradian M M; Serrati C; Chase T N
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Annals of neurology 1987;21(4):370-6.
1987: Juncos J L; Fabbrini G; Mouradian M M; Serrati C; Kask A M; Chase T N
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1987;50(2):194-8.
1987: Tamminga C A; Foster N L; Fedio P; Bird E D; Chase T N
Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism.
Neurology 1987;37(1):161-5.
1987: Chase T N; Juncos J; Serrati C; Fabbrini G; Bruno G
Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.
Advances in neurology 1987;45():477-80.
1987: Braun A; Fabbrini G; Mouradian M M; Serrati C; Barone P; Chase T N
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Journal of neural transmission 1987;68(1-2):41-50.
1987: Tamminga C A; Tanimoto K; Kuo S; Chase T N; Contreras P C; Rice K C; Jackson A E; O'Donohue T L
PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent.
Synapse (New York, N.Y.) 1987;1(5):497-504.
1986: Mouradian M M; Farah J M; Mohr E; Fabbrini G; O'Donohue T L; Chase T N
Spinal fluid CRF reduction in Alzheimer's disease.
Neuropeptides 1986;8(4):393-400.
1986: Braun A R; Chase T N
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.
European journal of pharmacology 1986;131(2-3):301-6.
1986: Martin A; Brouwers P; Lalonde F; Cox C; Teleska P; Fedio P; Foster N L; Chase T N
Towards a behavioral typology of Alzheimer's patients.
Journal of clinical and experimental neuropsychology 1986;8(5):594-610.
1986: Dawson T M; Barone P; Sidhu A; Wamsley J K; Chase T N
Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: use of the iodinated ligand [125I]SCH 23982.
Neuroscience letters 1986;68(3):261-6.
1986: Shults C; Steardo L; Barone P; Mohr E; Juncos J; Serrati C; Fedio P; Tamminga C A; Chase T N
Huntington's disease: effect of cysteamine, a somatostatin-depleting agent.
Neurology 1986;36(8):1099-102.
1986: Bruno G; Mohr E; Gillespie M; Fedio P; Chase T N
Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
Archives of neurology 1986;43(7):659-61.
1986: Naber D; Weinberger D R; Bullinger M; Polsby M; Chase T N
[Spasmodic torticollis. A study of symptoms, course, family history and psychopathology]
Der Nervenarzt 1986;57(4):238-43.
1986: Barone P; Davis T A; Braun A R; Chase T N
Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions.
European journal of pharmacology 1986;123(1):109-14.
1986: Schlesinger K; Pelleymounter M A; van de Kamp J; Bader D L; Stewart J M; Chase T N
Substance P facilitation of memory: effects in an appetitively motivated learning task.
Behavioral and neural biology 1986;45(2):230-9.
1986: Irving C S; Marks L; Klein P D; Foster N; Gadde P L; Chase T N; Samuel D
New evidence for taurine biosynthesis in man obtained from 18O2 inhalation studies.
Life sciences 1986;38(6):491-5.
1986: Foster N L; Chase T N; Patronas N J; Gillespie M M; Fedio P
Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography.
Annals of neurology 1986;19(2):139-43.
1986: Foster N; Chase T N
Cerebral metabolic rate of glucose and Alzheimer's disease.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1986;6(1):125-7.
1986: Foster N L; Tamminga C A; O'Donohue T L; Tanimoto K; Bird E D; Chase T N
Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease.
Neuroscience letters 1986;63(1):71-5.
1986: Simmons J T; Pastakia B; Chase T N; Shults C W
Magnetic resonance imaging in Huntington disease.
AJNR. American journal of neuroradiology 1986;7(1):25-8.
1986: Tamminga C A; Littman R L; Alphs L D; Chase T N; Thaker G K; Wagman A M
Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.
Psychopharmacology 1986;88(3):387-91.
1986: Barone P; Braun A R; Chase T N
D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients.
Clinical neuropharmacology 1986;9 Suppl 4():128-30.
1986: Braun A R; Barone P; Chase T N
Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors.
Advances in experimental medicine and biology 1986;204():151-66.
1986: Chase T N; Geoffrey V; Gillespie M; Burrows G H
Structural and functional studies of Gilles de la Tourette syndrome.
Revue neurologique 1986;142(11):851-5.
1986: Ludwig C L; Weinberger D R; Bruno G; Gillespie M; Bakker K; LeWitt P A; Chase T N
Buspirone, Parkinson's disease, and the locus ceruleus.
Clinical neuropharmacology 1986;9(4):373-8.
1986: Mohr E; Bruno G; Foster N; Gillespie M; Cox C; Hare T A; Tamminga C; Fedio P; Chase T N
GABA-agonist therapy for Alzheimer's disease.
Clinical neuropharmacology 1986;9(3):257-63.
1985: Tamminga C A; Foster N L; Chase T N
Reduced brain somatostatin levels in Alzheimer's disease.
The New England journal of medicine 1985;313(20):1294-5.
1985: Cohen S L; Knight M; Tamminga C A; Chase T N
A comparison of peripheral and central effects of CCK8 on water-reinforced operant responding.
European journal of pharmacology 1985;116(3):229-38.
1985: Steardo L; Knight M; Tamminga C A; Barone P; Kask A M; Chase T N
CCK26-33 degrading activity in brain and nonneural tissue: a metalloendopeptidase.
Journal of neurochemistry 1985;45(3):784-90.
1985: Massari V J; Shults C W; Park C H; Tizabi Y; Moody T W; Chronwall B M; Culver M; Chase T N
Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord.
Brain research 1985;343(2):268-74.
1985: Juncos J; Serrati C; Fabbrini G; Chase T N
Fluctuating levodopa concentrations and Parkinson's disease.
Lancet 1985;2(8452):440.
1985: Shults C W; Yajima H; Gullner H G; Chase T N; O'Donohue T L
Demonstration and distribution of kassinin-like material (substance K) in the rat central nervous system.
Journal of neurochemistry 1985;45(2):552-8.
1985: Knight M; Barone P; Tamminga C A; Steardo L; Chase T N
Cholecystokinin octapeptide analogues stable to brain proteolysis.
Peptides 1985;6(4):631-4.
1985: Tamminga C A; LeWitt P A; Chase T N
Cholecystokinin and neurotensin gradients in human CSF.
Archives of neurology 1985;42(4):354-5.
1985: Shults C W; Buck S H; Burcher E; Chase T N; O'Donohue T L
Distinct binding sites for substance P and neurokinin A (substance K): co-transmitters in rat brain.
Peptides 1985;6(2):343-5.
1985: Steardo L; Knight M; Tamminga C A; Chase T N
Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors.
Neuroscience letters 1985;54(2-3):319-25.
1985: Steardo L; Monteleone P; Tamminga C A; Canonico P L; Denman D; Scapagnini U; Chase T N
Differential responses in prolactin levels induced by naloxone in humans.
Psychoneuroendocrinology 1985;10(2):203-9.
1985: Newman R P; LeWitt P A; Shults C; Bruno G; Foster N L; Chase T N; Calne D B
Dystonia: treatment with bromocriptine.
Clinical neuropharmacology 1985;8(4):328-33.
1985: Bruno G; Ruggieri S; Chase T N; Bakker K; Tamminga C A
Caerulein treatment of Parkinson's disease.
Clinical neuropharmacology 1985;8(3):266-70.
1985: Chase T N; Barone P; Bruno G; Cohen S L; Juncos J; Knight M; Ruggeri S; Steardo L; Tamminga C A
Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric disease.
Annals of the New York Academy of Sciences 1985;448():553-61.
1985: Newman R P; Tamminga C A; Chase T N; LeWitt P A
EMD 23,448: effects of a putative dopamine autoreceptor agonist in chorea.
Journal of neural transmission 1985;61(1-2):125-9.
1985: Tamminga C A; Thaker G K; Chase T N
GABA dysfunction in the pathophysiology of tardive dyskinesia.
Psychopharmacology. Supplementum 1985;2():122-7.
1984: Foster N L; Chase T N; Mansi L; Brooks R; Fedio P; Patronas N J; Di Chiro G
Cortical abnormalities in Alzheimer's disease.
Annals of neurology 1984;16(6):649-54.
1984: Chase T N; Fedio P; Foster N L; Brooks R; Di Chiro G; Mansi L
Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography.
Archives of neurology 1984;41(12):1244-7.
1984: Chronwall B M; Chase T N; O'Donohue T L
Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons.
Neuroscience letters 1984;52(3):213-7.
1984: O'Donohue T L; Massari V J; Pazoles C J; Chronwall B M; Shults C W; Quirion R; Chase T N; Moody T W
A role for bombesin in sensory processing in the spinal cord.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1984;4(12):2956-62.
1984: Shults C W; Quirion R; Chronwall B; Chase T N; O'Donohue T L
A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system.
Peptides 1984;5(6):1097-128.
1984: Foster N L; Newman R P; LeWitt P A; Gillespie M M; Larsen T A; Chase T N
Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
Annals of neurology 1984;16(4):505-8.
1984: Foster N L; Newman R P; LeWitt P A; Gillespie M M; Chase T N
Treatment of resting tremor by beta-adrenergic blockade.
American heart journal 1984;108(4 Pt 2):1173-7.
1984: Knight M; Tamminga C A; Steardo L; Beck M E; Barone P; Chase T N
Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors.
European journal of pharmacology 1984;105(1-2):49-55.
1984: Knight M; Tamminga C A; Ito Y; Gardner J D; Chase T N
Purification of a cholecystokinin fragment peptide in the horizontal flow-through coil planet centrifuge.
Journal of chromatography 1984;301(1):277-81.
1984: Burcher E; Shults C W; Buck S H; Chase T N; O'Donohue T L
Autoradiographic distribution of substance K binding sites in rat gastrointestinal tract: a comparison with substance P.
European journal of pharmacology 1984;102(3-4):561-2.
1984: Helke C J; Shults C W; Chase T N; O'Donohue T L
Autoradiographic localization of substance P receptors in rat medulla: effect of vagotomy and nodose ganglionectomy.
Neuroscience 1984;12(1):215-23.
1984: Keeler J R; Shults C W; Chase T N; Helke C J
The ventral surface of the medulla in the rat: pharmacologic and autoradiographic localization of GABA-induced cardiovascular effects.
Brain research 1984;297(2):217-24.
1984: Denaro A; Tamminga C A; Ruggieri S; Chase T N; Agnoli A
State of DA/ACh balance after chronic treatment with haloperidol and with THIP in rats.
Advances in neurology 1984;40():141-7.
1984: Chase T N; Foster N L; Fedio P; Brooks R; Mansi L; Kessler R; Di Chiro G
Gilles de la tourette syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method.
Annals of neurology 1984;15 Suppl():S175.
1984: Chase T N; Foster N L; Fedio P; Brooks R; Mansi L; Di Chiro G
Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography.
Annals of neurology 1984;15 Suppl():S170-4.
1984: Chase T N; Foster N L; Fedio P; Mansi L; Brooks R; Kessler R; Di Chiro G
Cognitive and cerebral metabolic function in early and advanced Alzheimer's disease.
Monographs in neural sciences 1984;11():176-9.
1983: Durso R; Tamminga C A; Ruggeri S; Denaro A; Kuo S; Chase T N
Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease.
Journal of neurology, neurosurgery, and psychiatry 1983;46(12):1134-7.
1983: Doi H; Chen K M; Chase T N; Yanagihara R T; Uebayashi Y
[Effect of L-dopa on clinical duration and quality of life of patients with Parkinsonism-dementia in Guam]
Rinsho shinkeigaku = Clinical neurology 1983;23(11):935-42.
1983: Papadopoulos N M; LeWitt P A; Newman R P; Raphaelson M I; Chase T N
A unique protein in normal human cerebrospinal fluid.
Clinical chemistry 1983;29(10):1842-4.
1983: Schlesinger K; Lipsitz D U; Peck P L; Pelleymounter M A; Stewart J M; Chase T N
Substance P enhancement of passive and active avoidance conditioning in mice.
Pharmacology, biochemistry, and behavior 1983;19(4):655-61.
1983: Cohen S L; Knight M; Tamminga C A; Chase T N
Minimized tolerance to the suppressive effects of CCK8 on operant responding.
Behavioral and neural biology 1983;39(1):123-7.
1983: Durso R; Tamminga C A; Denaro A; Ruggeri S; Chase T N
Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease.
Neurology 1983;33(9):1229-32.
1983: Schlesinger K; Lipsitz D U; Peck P L; Pelleymounter M A; Stewart J M; Chase T N
Substance p reversal of electroconvulsive shock and cycloheximide-induced retrograde amnesia.
Behavioral and neural biology 1983;39(1):30-9.
1983: Foster N L; Chase T N; Fedio P; Patronas N J; Brooks R A; Di Chiro G
Alzheimer's disease: focal cortical changes shown by positron emission tomography.
Neurology 1983;33(8):961-5.
1983: Wolf S S; Moody T W; Quirion R; Shults C W; Chase T N; O'Donohue T L
Autoradiographic visualization of substance P receptors in rat brain.
European journal of pharmacology 1983;91(1):157-8.
1983: Chase T N; Foster N L; Mansi L
Alzheimer's disease and the parietal lobe.
Lancet 1983;2(8343):225.
1983: Quirion R; Shults C W; Moody T W; Pert C B; Chase T N; O'Donohue T L
Autoradiographic distribution of substance P receptors in rat central nervous system.
Nature 1983;303(5919):714-6.
1983: Foster N L; Chase T N; Denaro A; Hare T A; Tamminga C A
THIP treatment of Huntington's disease.
Neurology 1983;33(5):637-9.
1983: Foster N L; Chase T N
Diffuse involvement in progressive aphasia.
Annals of neurology 1983;13(2):224-5.
1983: Cohen S L; Knight M; Tamminga C A; Chase T N
Tolerance to the anti-avoidance properties of cholecystokinin-octapeptide.
Peptides 1983;4(1):67-70.
1982: Shults C W; Quirion R; Jensen R T; Moody T W; O'Donohue T L; Chase T N
Autoradiographic localization of substance P receptors using 125I substance P.
Peptides 1982;3(6):1073-5.
1982: Cohen S L; Knight M; Tamminga C A; Chase T N
Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy.
European journal of pharmacology 1982;83(3-4):213-22.
1982: Durso R; Fedio P; Brouwers P; Cox C; Martin A J; Ruggieri S A; Tamminga C A; Chase T N
Lysine vasopressin in Alzheimer disease.
Neurology 1982;32(6):674-7.
1981: Tamminga C A; Tighe P J; Chase T N; DeFraites E G; Schaffer M H
Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report.
Archives of general psychiatry 1981;38(2):167-8.
1980: Nutt J G; Mrox E A; Leeman S E; Williams A C; Engel W K; Chase T N
Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.
Neurology 1980;30(12):1280-5.
1980: Williams A C; Levine R A; Chase T N; Lovenberg W; Calne D B
CFS hydroxylase cofactor levels in some neurological diseases.
Journal of neurology, neurosurgery, and psychiatry 1980;43(8):735-8.
1980: Williams A; Papadopoulos N; Chase T N
Demonstration of CSF gamma-globulin banding in presenile dementia.
Neurology 1980;30(8):882-4.
1980: Tamminga C A; Chase T N
Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia.
Archives of neurology 1980;37(4):204-5.
1980: Beasley B L; Nutt J G; Davenport R W; Chase T N
Treatment with tryptophan of levodopa-associated psychiatric disturbances.
Archives of neurology 1980;37(3):155-6.
1980: Chase T N; Tamminga C A
Pharmacologic studies of tardive dyskinesia.
Advances in biochemical psychopharmacology 1980;24():457-61.
1979: Tamminga C A; Crayton J W; Chase T N
Improvement in tardive dyskinesia after muscimol therapy.
Archives of general psychiatry 1979;36(5):595-8.
1979: Nagano Y; Tsubaki T; Chase T N
Endocrinologic regulation of carbohydrate metabolism. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam.
Archives of neurology 1979;36(4):217-20.
1978: Tamminga C A; Neophytides A; Chase T N; Frohman L A
Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist.
The Journal of clinical endocrinology and metabolism 1978;47(6):1348-51.
1978: Nutt J G; Rosin A J; Eisler T; Calne D B; Chase T N
Effect of an opiate antagonist on movement disorders.
Archives of neurology 1978;35(12):810-1.
1978: Nutt J G; Rosin A; Chase T N
Treatment of Huntington disease with a cholinergic agonist.
Neurology 1978;28(10):1061-4.
1978: Weir R L; Glaubiger G; Chase T N
Inhibition of fast axoplasmic transport by acrylamide.
Environmental research 1978;17(2):251-5.
1978: Nagano Y; Tsubaki T; Miyashita M; Ebitani I; Chase T N
[Abnormal carbohydrate metabolism in amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam (author's transl)]
Rinsho shinkeigaku = Clinical neurology 1978;18(8):486-90.
1978: Tamminga C A; Crayton J W; Chase T N
Muscimol: GABA agonist therapy in schizophrenia.
The American journal of psychiatry 1978;135(6):746-7.
1978: Perlow M; Ebert M H; Gordon E K; Ziegler M G; Lake C R; Chase T N
The circadian variation of catecholamine metabolism in the subhuman primate.
Brain research 1978;139(1):101-13.
1977: Pericic D; Walters J R; Chase T N
Effect of diazepam and pentobarbital on aminooxyacetic acid-induced accumulation on GABA.
Journal of neurochemistry 1977;29(5):839-46.
1977: Gartrell N K; Loriaux D L; Chase T N
Plasma testosterone in homosexual and heterosexual women.
The American journal of psychiatry 1977;134(10):1117-8.
1977: Lightfoote W E; Molinari G F; Chase T N
Modification of cerebral ischemic damage by anesthetics.
Stroke; a journal of cerebral circulation 1977;8(5):627-8.
1977: Perlow M J; Gordon E K; Ebert M E; Hoffman H J; Chase T N
The circadian variation in dopamine metabolism in the subhuman primate.
Journal of neurochemistry 1977;28(6):1381-3.
1977: Perlow M J; Festoff B; Gordon E K; Ebert M H; Johnson D K; Chase T N
Daily fluctuation in the concentration of cAMP in the conscious primate brain.
Brain research 1977;126(2):391-6.
1977: Beasley B L; Davenport R W; Chase T N
Fenfluramine hydrochloride treatment of parkinsonism.
Archives of neurology 1977;34(4):255-6.
1976: Shetty T; Chase T N
Central monoamines and hyperkinase of childhood.
Neurology 1976;26(10):1000-2.
1976: Kartzinel R; Ebert M H; Chase T N
Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.
Neurology 1976;26(10):992-6.
1976: Chase T N; Eng N; Gordon E K
Biochemical aids in the diagnosis of Parkinson's disease.
Annals of clinical and laboratory science 1976;6(1):4-10.
1976: Shoulson I; Chase T N
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Neuropharmacology 1976;15(1):25-7.
1976: Shoulson I; Kartzinel R; Chase T N
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid.
Neurology 1976;26(1):61-3.
1976: Chase T N; Shoulson I; Carter A C
Serotonergic functions in man.
Monographs in neural sciences 1976;3():8-14.
1976: Perlow M; Gordon E; Ebert M; Festoff B; Chase T N
The circadian pattern of catcholamine metabolites and cAMP in the cerebrospinal fluid of subhuman primates.
Transactions of the American Neurological Association 1976;101():279-80.
1976: Kartzinel R; Perlow M D; Carter A C; Chase T N; Calne D B; Shoulson I
Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea.
Transactions of the American Neurological Association 1976;101():53-6.
1976: Chase T N
Rational approaches to the pharmacotherapy of chorea.
Research publications - Association for Research in Nervous and Mental Disease 1976;55():337-50.
1975: Shoulson I; Glaubiger G A; Chase T N
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
Neurology 1975;25(12):1144-8.
1975: Thach B T; Chase T N; Bosma J F
Oral facial dyskinesia accociated with prolonged use of antihistaminic decongestants.
The New England journal of medicine 1975;293(10):486-7.
1975: Shoulson I; Chase T N; Roberts E; Van Balgooy J N
Letter: Huntington's disease: treatment with imidazole-4-acetic acid.
The New England journal of medicine 1975;293(10):504-5.
1975: Shoulson I; Chase T N
Fenfluramine in man: hypophagia associated with diminished serotonin turnover.
Clinical pharmacology and therapeutics 1975;17(5):616-21.
1975: Chase T N; Shoulson I
Behavioural and biochemical effects of fenfluramine in patients with neurologic disease.
Postgraduate medical journal 1975;51 Suppl 1():105-9.
1975: Chase T N; Shoulson I
Dopaminergic mechanisms in patients with extrapyramidal disease.
Advances in neurology 1975;9():359-66.
1975: Pelton E W; Chase T N
L-Dopa and the treatment of extrapyramidal disease.
Advances in pharmacology and chemotherapy 1975;13():253-304.
1975: Shoulson I; Chase T N
Huntington's disease.
Annual review of medicine 1975;26():419-36.
1974: Shoulson I; Chase T N
Letter: Fenfluramine and dyskinesias.
The New England journal of medicine 1974;291(16):850-1.
1974: Chase T N
Fusaric acid in Parkinson's disease.
Neurology 1974;24(7):637-9.
1974: Chase T N
Proceedings: Clinical studies of dopaminergic mechanisms.
Psychopharmacology bulletin 1974;10(3):43-4.
1974: Chase T N; Woods A C; Lipton M A; Morris C E
Hypothalamic releasing factors and Parkinson disease.
Archives of neurology 1974;31(1):55-6.
1974: Chase T N; Woods A C; Glaubiger G A
Parkinson disease treated with a suspected dopamine receptor agonist.
Archives of neurology 1974;30(5):383-6.
1974: Pérez-Cruet J; Chase T N; Murphy D L
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans.
Nature 1974;248(450):693-5.
1974: Carman J S; Shoulson I; Chase T N
Letter: Huntington's chorea treated with lithium carbonate.
Lancet 1974;1(7861):811.
1974: Holden E M; Brody J A; Chase T N
Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
Neurology 1974;24(3):263-5.
1974: Chase T N; Balch T S; Jacobowitz D M
Dopamine histofluorescence in post-mortem specimens of human and rat striatum.
Journal of psychiatric research 1974;11():281-2.
1974: Chase T N
Clinical studies of dopaminergic mechanisms.
Advances in biochemical psychopharmacology 1974;12(0):427-34.
1974: Chase T N
Serotonergic-dopaminergic interactions and extrapyramidal function.
Advances in biochemical psychopharmacology 1974;11(0):377-85.
1974: Chase T N
Serotonergic mechanisms and extrapyramidal function in man.
Advances in neurology 1974;5():31-9.
1973: Chase T N; Holden E M; Brody J A
Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis.
Archives of neurology 1973;29(5):328-33.
1973: Chase T N
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Archives of neurology 1973;29(5):349-51.
1973: Cramer H; Ng L K; Chase T N
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease.
Archives of neurology 1973;29(3):197-9.
1973: Chase T N; Gordon E K; Ng L K
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
Journal of neurochemistry 1973;21(3):581-7.
1973: Woods A C; Chase T N
M.I.F.: effect on levodopa dyskinesias in man.
Lancet 1973;2(7827):513.
1973: Woods A C; Glaubiger G A; Chase T N
Sustained-release levodopa.
Lancet 1973;1(7816):1391.
1973: Fermaglich J; Chase T N
Methyldopa or methyldopahydrazine as levodopa synergists.
Lancet 1973;1(7814):1261-2.
1973: Gordon E K; Oliver J; Goodwin F K; Chase T N; Post R M
Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid.
Neuropharmacology 1973;12(4):391-6.
1973: Balch T S; Chase T N; Jacobowitz D M
Dopamine histofluorescence: restoration in mammalian brain tissues prepared several hours post mortem.
Brain research 1973;52():419-23.
1973: Weir R L; Chase T N; Ng L K; Kopin I J
5-hydroxyindoleacetic cid in spinal fluid: relative contribution from brain and spinal cord.
Brain research 1973;52():409-12.
1973: Donnelly E F; Chase T N
Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
Diseases of the nervous system 1973;34(2):119-23.
1973: Chase T N; Murphy D L
Serotonin and central nervous system function.
Annual review of pharmacology 1973;13():181-97.
1972: Mendell J R; Murphy D L; Engel W K; Chase T N; Gordon E
Catecholamines and indoleamines in patients with Duchenne muscular dystrophy.
Archives of neurology 1972;27(6):518-20.
1972: Chase T N; Ng L K
Central monoamine metabolism in Parkinson's disease.
Archives of neurology 1972;27(6):486-91.
1972: Ng L K; Chase T N; Colburn R W; Kopin I J
Release of ( 3 H)dopamine by L-5-hydroxytryptophan.
Brain research 1972;45(2):499-505.
1972: Chase T N
Serotonergic mechanisms in Parkinson's disease.
Archives of neurology 1972;27(4):354-6.
1972: Lott I T; Chase T N; Murphy D L
Down's syndrome: transport, storage, and metabolism of serotonin in blood platelets.
Pediatric research 1972;6(9):730-5.
1972: Lott I T; Murphy D L; Chase T N
Down's syndrome. Central monoamine turnover in patients with diminished platelet serotonin.
Neurology 1972;22(9):967-72.
1972: Ng L K; Chase T N; Colburn R W; Kopin I J
L-dopa in Parkinsonism. A possible mechanism of action.
Neurology 1972;22(7):688-96.
1972: Cramer H; Ng L K; Chase T N
Effect of probenecid on levels of cyclic AMP in human cerebrospinal fluid.
Journal of neurochemistry 1972;19(6):1601-2.
1972: Chase T N; Ng L K; Watanabe A M
Parkinson's disease. Modification by 5-hydroxytryptophan.
Neurology 1972;22(5):479-84.
1972: Chase T N; Watanabe A M
Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
Neurology 1972;22(4):384-92.
1972: Chase T N; Watanabe A M; Brodie K H; Donnelly E F
Huntington's chorea. Effect of serotonin depletion.
Archives of neurology 1972;26(3):282-4.
1972: Chase T N
Drug-induced extrapyramidal disorders.
Research publications - Association for Research in Nervous and Mental Disease 1972;50():448-71.
1971: Schnur J A; Chase T N; Brody J A
Parkinsonism-dementia of Guam: treatment with L-dopa.
Neurology 1971;21(12):1236-42.
1971: Chase T N; Ng L K
Probenecid test in Parkinson's disease.
Lancet 1971;2(7736):1265-6.
1971: Weiss J L; Cohn C K; Chase T N
Reduction of catechol-O-methyl-transferases activity by chronic L-dopa therapy.
Nature 1971;234(5326):218-9.
1971: Mendell J R; Chase T N; Engel W K
Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa.
Archives of neurology 1971;25(4):320-5.
1971: Wyatt R J; Chase T N; Kupfer D J; Scott J; Snyder F
Brain catecholamines and human sleep.
Nature 1971;233(5314):63-5.
1971: Vesell E S; Ng L; Passananti G T; Chase T N
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor.
Lancet 1971;2(7720):370.
1971: Weiss J L; Ng L K; Chase T N
Long-lasting dyskinesia induced by levodopa.
Lancet 1971;1(7707):1016-7.
1971: Ng K Y; Chase T N; Colburn R W; Kopin I J
Dopamine: stimulation-induced release from central neurons.
Science (New York, N.Y.) 1971;172(982):487-9.
1971: Chase T N; Breese G R; Gordon E K; Kopin I J
Catecholamine metabolism in the dog: comparison of intravenously and intraventricularly administered [14C]dopamine and [3H]norepinephrine.
Journal of neurochemistry 1971;18(1):135-40.
1971: Mendell J R; Chase T N; Engel W K
Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-dopa.
Transactions of the American Neurological Association 1971;96():284-6.
1971: Weiss J L; Chase T N
Levodopa in Parkinsonism.
Drugs 1971;2(4):257-61.
1970: Chase T N
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
Neurology 1970;20(12):36-40.
1970: Chase T N
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
Neurology 1970;20(12):Suppl:36-40.
1970: Wyatt R J; Chase T N; Scott J; Snyder F; Engleman K
Effect of L-dopa on the sleep of man.
Nature 1970;228(5275):999-1001.
1970: Chase T N
Biochemical and pharmacologic studies of dystonia.
Neurology 1970;20(11):122-30.
1970: Chase T N
5-hydroxytryptophan in parkinsonism.
Lancet 1970;2(7681):1029-30.
1970: Ng K Y; Chase T N; Kopin I J
Drug-induced release of 3H-norepinephrine and 3H-serotonin from brain slices.
Nature 1970;228(5270):468-9.
1970: Ng K Y; Chase T N; Colburn R W; Kopin I J
L-Dopa-induced release of cerebral monoamines.
Science (New York, N.Y.) 1970;170(953):76-7.
1970: Watanabe A M; Chase T N; Cardon P V
Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.
Clinical pharmacology and therapeutics 1970;11(5):740-6.
1970: Chase T N; Schnur J A; Gordon E K
Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders.
Neuropharmacology 1970;9(3):265-8.
1970: Brody J A; Chase T N; Gordon E K
Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam.
The New England journal of medicine 1970;282(17):947-50.
1970: Chase T N; Katz R I; Kopin I J
Effect of diazepam on fate of intracisternally injected serotonin-C14.
Neuropharmacology 1970;9(2):103-8.
1970: Mendell J R; Engel W K; Chase T N
Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.
Lancet 1970;1(7647):593-4.
1970: Breese G R; Chase T N; Kopin I J
Effect of monoamine oxidase inhibitors on the disposition of intracisternally administrred metaraminol-3H.
Biochemical pharmacology 1970;19(2):525-32.
1970: Katz R I; Chase T N
Neurohumoral mechanisms in the brain slice.
Advances in pharmacology and chemotherapy 1970;8():1-30.
1969: Katz R I; Chase T N; Kopin I J
Effect of ions on stimulus-induced release of amino acids from mammalian brain slices.
Journal of neurochemistry 1969;16(3):961-7.
1969: Chase T N; Katz R I; Kopin I J
Release of [3H]serotonin from brain slices.
Journal of neurochemistry 1969;16(4):607-15.
1969: Breese G R; Chase T N; Kopin I J
Metabolism of tyramine-3H and octopamine-3H by rat brain.
Biochemical pharmacology 1969;18(4):863-9.
1969: Bunney W E; Janowsky D S; Goodwin F K; Davis J M; Brodie H K; Murphy D L; Chase T N
Effect of L-DOPA on depression.
Lancet 1969;1(7600):885-6.
1969: Breese G R; Chase T N; Kopin I J
Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain.
The Journal of pharmacology and experimental therapeutics 1969;165(1):9-13.
1969: Chase T N; Katz R I; Kopin I J
Effect of anticonvulsants on brain serotonin.
Transactions of the American Neurological Association 1969;94():236-8.
1969: Katz R I; Chase T N; Koplin I J
Electrically stimulated release of norepinephrine-H3 and serotonin-H3 from mammalian brain slices: a model for studying the effects of drugs on putative central neurotransmitters.
Transactions of the American Neurological Association 1969;94():284-6.
1968: Katz R I; Chase T N; Kopin I J
Evoked release of norepinephrine and serotonin from brain slices: inhibitoon by lithium.
Science (New York, N.Y.) 1968;162(852):466-7.
1968: Chase T N; Moretti L; Prensky A L
Clinical and electroencephalographic manifestations of vascular lesions of the pons.
Neurology 1968;18(4):357-68.
1968: Chase T N; Rosman N P; Price D L
The cerebral syndromes associated with dissecting aneurysm of the aorta. A clinicopathological study.
Brain : a journal of neurology 1968;91(1):173-90.
1968: Chase T N; Kopin I J
Stimulus-induced release of substances from olfactory bulb using the push-pull cannula.
Nature 1968;217(5127):466-7.
1968: Chase T N; Breese G R; Carpenter D O; Schanberg S M; Kopin I J
Stimulation-induced release of serotonin.
Advances in pharmacology 1968;6(Pt A):351-64.
1967: Chase T N; Breese G R; Kopin I J
Serotonin release from brain slices by electrical stimulation: regional differences and effect of LSD.
Science (New York, N.Y.) 1967;157(795):1461-3.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Thomas Chase

Research Profile (preview)

Disorders

Chemicals & Drugs

Living Beings

Anatomy

Concepts & Ideas

Activities & Behaviors

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Thomas Chase (preview)

All Publications